

**Virtual MD Anderson Proton Therapy Training Webinar - Thoracic/Liver 4/30/2021**

**Presented by**

|  |
| --- |
| Joe Chang, MD, PhD |
| Professor |
| UT MD Anderson Cancer Center |
|  |
| Eugene J Koay, MD, PhD |
| MD Anderson Cancer Center |
|  |
| Yupeng Li, MS |
| UT MD Anderson Cancer Center |
|  |
| Zhongxing Liao, MD |
| Dr. |
| MDACC |
|  |
| Steven Lin, MD, PhD |
| Associate Professor |
| MD Anderson Cancer Center |
|  |
| Ethan B Ludmir, MD |
| Assistant Professor |
| The University of Texas MD Anderson Cancer Center |
|  |
| Matthew S Ning, MD, MPH |
| Assistant Professor |
| The University of Texas MD Anderson Cancer Center |
|  |
| Kevin Tran, BS |
| Medical Dosimetrist |
| MD Anderson Cancer Center |
|  |
| Xiaodong Zhang, PhD |
| University of Texas, MD Anderson Cancer Center |
|  |

**Friday April 30, 2021**

**9:00 AM**

**Online**

**Target Audience:**

Specialties: Diagnostic Radiology, Nuclear Medicine, Radiation Oncology

Professions: Physician (MD or DO), Other

**Description:**

Since 2006, the MD Anderson Proton Therapy Center in Houston has treated more than 10,000 patients with the most advanced radiation treatment available. Proton therapy has allowed MD Anderson to treat cancer with power and precision while sparing healthy tissue and reducing the risk of side effects during and following treatment. MD Anderson has published more than 570 manuscripts on proton therapy and is currently running numerous clinical trials to define the value of proton therapy. We are the first in North America to treat patients with Intensity-Modulated Proton Therapy (IMPT) and continue to pioneer in the treatment of each disease site using IMPT.

MD Anderson is well positioned to educate and expand the global knowledge in the developing field of proton therapy. As the medical industry, insurance companies and the public become more aware of the benefits of utilizing proton therapy, there remains a gap in the knowledge in this field of treatment as proton therapy expands rapidly both nationally and internationally. Proton therapy is very different from photon therapy and the goal of the MD Anderson Proton Therapy Training Program is to bridge this knowledge gap by teaching the value of proton therapy by disease site. Our Proton Therapy Training Program aims to provide the knowledge and expertise to physicians, physicists, dosimetrists, therapists and administrators who are planning to treat patients with IMPT.

**Learning Objectives:**

1 Incorporate the skills learned through interactive virtual sessions to better prepare for proton therapy treatments, thus improving patient outcomes

2 Incorporate knowledge on the responsibilities of physicians, physicists, dosimetrists and therapists in the treatment of proton therapy and the importance of their roles to provide optimal patient care.Incorporate knowledge on the responsibilities of dosimetrists, physicists and nurses in the treatment of proton therapy and the importance of their roles to provide optimal patient care

3 Apply the knowledge of treatment planning and clinical operations to perform proton therapy in respective centers/locations

4 Gain a greater appreciation and perspective of the steps and personnel needed to perform quality proton therapy



**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 2.75 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:**

No commercial support has been received for this activity.

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of commercial interest/Nature of relationship** |
| Steven Frank, MD | Activity Co-Director/Chair | Grant or research support-Other-Hitachi|Paid consultant-Other-Varian|Paid consultant-Boston Scientific Corporation|Grant or research support-Eli Lilly and Company - 01/26/2021 |
| Brandon Gunn, MD | Activity Co-Director/Chair | Nothing to disclose - 01/25/2021 |
| Mayankkumar Amin, M.Sc. | Other Planning Committee Member | Nothing to disclose - 01/25/2021 |
| Rola Georges, MS | Other Planning Committee Member | Nothing to disclose - 03/03/2021 |
| Kelley Gilpin, BA | Other Planning Committee Member | Nothing to disclose - 01/15/2021 |
| Susan Mcgovern, MD, PhD | Other Planning Committee Member | Nothing to disclose - 03/11/2021 |
| Xiaorong Zhu, PhD | Other Planning Committee Member | Membership on advisory committees or review panels, board membership, etc.-Other-Mevion Medical Systems - 01/28/2021 |
| Joe Chang, MD PhD | Faculty | Grant or research support-Bristol-Myers Squibb|Membership on advisory committees or review panels, board membership, etc.-Other-Legion|Membership on advisory committees or review panels, board membership, etc.-Other-Global Oncology One - 12/11/2020 |
| Eugene Koay, MD PhD | Faculty | Consulting Fee-RenovoRx-|Grant or research support-Philips Medical Systems, Inc.-|Grant or research support-GE Healthcare Bio-Sciences-|Royalties-Taylor and Francis, LLC- - 04/19/2021 |
| Yupeng Li, MS | Faculty | Nothing to disclose - 03/22/2021 |
| Zhongxing Liao, MD | Faculty | Nothing to disclose - 01/19/2021 |
| Steven Lin, MD PhD | Faculty | Grant or research support-Other-Beyond Spring Pharmaceuticals|Grant or research support-Other-Hitachi Chemical Diagnostics|Paid consultant-Other-XRAD Therapeutics|Membership on advisory committees or review panels, board membership, etc.-AstraZeneca|Membership on advisory committees or review panels, board membership, etc.-Other-STCube Pharmaceuticals - 01/05/2021 |
| Ethan Ludmir, MD | Faculty | Nothing to disclose - 03/16/2021 |
| Matthew Ning, MD MPH | Faculty | Nothing to disclose - 03/12/2021 |
| Kevin Tran, BS | Faculty | Nothing to disclose - 02/08/2021 |
| Xiaodong Zhang, PhD | Faculty | Nothing to disclose - 03/01/2021 |

**Hardware & Software Requirements:**

If this activity includes a virtual meeting, the technical requirements are as follows:

**System Requirements:**

Internet Connection – broadband wired or wireless (3G or 4G/LTE)

Speakers – built-in or wireless Bluetooth

**Windows:**

Internet Browser – Internet Explorer 11+, Edge 12+, Firefox 27+, Chrome 30+

Operating System – Windows 10 Home, Pro, or Enterprise. S Mode is not supported.

**Apple:**

Internet Browser – Safari 7+, Firefox 27+, Chrome 30+

Operating System macOS 10.9 or later

**Processor Requirements:**

Minimum – Single-core 1GHz or higher

Recommended – Dual-core 2GHz or higher (Intel i3/i5/i7 or AMD equivalent)

**RAM Requirements:**

Minimum – N/A

Recommended – 4GB

**Bandwidth:**

50 - 70kbps (down)

**Supported Tablet and Mobile Devices:**

Surface PRO 2 or higher and running Windows 8.1 or higher

iOS and Android devices

Blackberry devices